Next Article in Journal
Noncoding Subgenomic Flavivirus RNA: Multiple Functions in West Nile Virus Pathogenesis and Modulation of Host Responses
Next Article in Special Issue
Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
Previous Article in Journal
HSV-2 Vaccine: Current Status and Insight into Factors for Developing an Efficient Vaccine
Previous Article in Special Issue
Recombinant Salmonella enterica Serovar Typhimurium as a Vaccine Vector for HIV-1 Gag
Article Menu

Export Article

Open AccessCommunication
Viruses 2014, 6(2), 391-403; doi:10.3390/v6020391

Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines

1
Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Via GB. Grassi 74, 20157 Milan, Italy
2
Department of Chemistry, University of Milan, Via C.Golgi 19, 20133 Milan, Italy
3
Unit of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Via GB. Grassi 74, 20157 Milan, Italy
4
Department of Pathophysiology and Transplantation, University of Milan, Via F.lli VCervi 93, 20090 Milan, Italy
5
Don C. Gnocchi Foundation, IRCCS, Via Capecelatro 66, 20148 Milan, Italy
*
Author to whom correspondence should be addressed.
Received: 22 November 2013 / Revised: 7 January 2014 / Accepted: 20 January 2014 / Published: 27 January 2014
(This article belongs to the Special Issue AIDS Vaccine 2014)
View Full-Text   |   Download PDF [1030 KB, uploaded 12 May 2015]   |  

Abstract

The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated. View Full-Text
Keywords: vaccine; HIV-1; adjuvant; DC-SIGN; innate immunity; glycomimetic compounds vaccine; HIV-1; adjuvant; DC-SIGN; innate immunity; glycomimetic compounds
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Berzi, A.; Varga, N.; Sattin, S.; Antonazzo, P.; Biasin, M.; Cetin, I.; Trabattoni, D.; Bernardi, A.; Clerici, M. Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines. Viruses 2014, 6, 391-403.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top